Breaking News

Endo Licenses BioDelivery’s Pain Drug

BEMA Buprenorphine broadens Endo's pain portfolio

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Endo Pharmaceuticals has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International for BEMA Buprenorphine, a transmucosal form of buprenorphine that incorporates a bioerodible mucoadhesive (BEMA) technology. The drug is currently in Phase III trials for the treatment of moderate to severe chronic pain. BioDelivery Sciences will receive an upfront payment of $30 million, royalties on sales, and as much as $150 million in milestones based on the achie...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters